Loading...
Loading...
Browse all stories on DeepNewz
VisitPercentage increase in first-time Adderall prescriptions among young bankers by end of 2025?
0-10% • 25%
11-20% • 25%
21-30% • 25%
Above 30% • 25%
Data from healthcare analytics firms like Truveta or similar sources
Report Reveals 27% Rise in Adderall Prescriptions as Young Wall Street Bankers Use Stimulants for 22-Hour Work Days
Dec 16, 2024, 10:50 AM
A recent report highlights the increasing use of ADHD medications, particularly Adderall and Vyvanse, among young bankers on Wall Street. Interviews with over 50 current and former investment bankers reveal that many view these stimulants as essential tools to manage the long hours and intense pressure of their jobs. The report indicates that the use of these drugs is openly discussed in workplaces, with some bankers reportedly taking ever-increasing doses to cope with demanding 100-hour work weeks. A doctor who prescribes ADHD medications noted that many patients consider stimulants akin to multivitamins or dietary supplements. Data from Truveta shows a 27% rise in first-time Adderall prescriptions, underscoring the growing reliance on these substances in the finance sector. The findings raise concerns about a potential drug problem in the industry, as some bankers reportedly resort to snorting crushed Adderall to endure grueling workdays that can stretch up to 22 hours.
View original story
Yes • 50%
No • 50%
Yes • 50%
No • 50%
SEC • 25%
FINRA • 25%
Department of Labor • 25%
Other • 25%
Goldman Sachs • 25%
JP Morgan • 25%
Morgan Stanley • 25%
Other • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Less than 5% • 25%
5% to 10% • 25%
10.1% to 20% • 25%
More than 20% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 50% • 25%
50%-70% • 25%
70%-90% • 25%
More than 90% • 25%
Yes • 50%
No • 50%
Less than 50% • 25%
50% to 100% • 25%
100% to 150% • 25%
More than 150% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
No • 50%
Yes • 50%
Other • 25%
FINRA • 25%
FDA • 25%
SEC • 25%